Dr. Blackwell Discusses the HER2CLIMB Study in HER2+ Breast Cancer

March 7, 2018
Kimberly L. Blackwell, MD

Kimberly L. Blackwell, MD, medical oncologist, Duke Cancer Institute, discusses the HER2CLIMB study in patients with HER2-positive breast cancer.

Kimberly L. Blackwell, MD, medical oncologist, Duke Cancer Institute, discusses the HER2CLIMB study in patients with HER2-positive breast cancer.

The HER2CLIMB trial is currently investigating tucatinib (ONT-380), a novel small molecule HER2 inhibitor, in a triplet regimen (NCT02614794). Tucatinib may have the ability to penetrate the blood-brain barrier, making it a potentially beneficial option for patients with HER2-positive breast cancer who have developed brain metastases. In the study, tucatinib and trastuzumab (Herceptin) were combined with capecitabine in patients with unresectable locally advanced or metastatic HER2-positive disease with or without brain metastases.

Blackwell says that the findings of this study may provide efficacy information on whether tucatinib, as a small molecule inhibitor, might prevent progression of brain metastases when added to the regimen of capecitabine and trastuzumab.

x